Registry Collecting Data on a Rare Blood Cancer Called BPDCN
Collects information on patients with a rare blood cancer, BPDCN, and their treatments.
Plain-language title generated from the registry record
Registry title: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry
Key facts
- Where
- Kuwait City, KuwaitSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The registry is looking for people with a diagnosis of blastic plasmacytoid dendritic cell neoplasm (BPDCN), a very rare blood cancer. It collects data on how the disease is treated.
- Sex
- All sexes can join.
- Disease stage
- A diagnosis of BPDCN. No stage is named.
Read by machine on 12 November 2026.
Where in Kuwait
- Department of hematology, Kuwait Cancer Control CenterKuwait City, KuwaitContact: Ahmad Alhuraiji, MD, MRCP(UK)Taking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Immune Oncology Research Institute
- Trial code
- NCT05430971
- Record updated
- 5 June 2026
- Original description
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a very rare hematologic malignancy. Despite recent advances, at present there is no consensus on the optimal treatment of BPDCN. The optimal therapy of disease remains to be determined, and due to the rarity of cases, there is a need for international collaboration to collect data on BPDCN clinical presentations, diagnostics, treatment regimens and outcomes. Therefore, the objectives of this study are: (1) to build a large database of patients with BPDCN, (2) to investigate the characteristics and outcome of the disease with different treatment regimens, (3) to evaluate prognostic factors, and (4) to generate data-based prospective treatment recommendations.Read full original descriptionShow less
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a very rare hematologic malignancy. Despite recent advances, at present there is no consensus on the optimal treatment of BPDCN. The optimal therapy of disease remains to be determined, and due to the rarity of cases, there is a need for international collaboration to collect data on BPDCN clinical presentations, diagnostics, treatment regimens and outcomes. Therefore, the objectives of this study are: (1) to build a large database of patients with BPDCN, (2) to investigate the characteristics and outcome of the disease with different treatment regimens, (3) to evaluate prognostic factors, and (4) to generate data-based prospective treatment recommendations.
Inclusion: Diagnosis of BPDCN; Signed informed consent form for prospective patients.
Exclusion: -.